431 related articles for article (PubMed ID: 12858359)
1. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
3. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
Ross RW; Manola J; Hennessy K; Galsky M; Scher H; Small E; Kelly WK; Kantoff PW
Clin Cancer Res; 2005 Jul; 11(14):5195-8. PubMed ID: 16033836
[TBL] [Abstract][Full Text] [Related]
6. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
7. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
8. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
9. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
11. Predictors of androgen independence in metastatic prostate cancer.
Sim HG; Lau WK; Cheng CW
BJU Int; 2004 Jun; 93(9):1221-4. PubMed ID: 15180610
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
14. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
15. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
17. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Eaton CL; Wells JM; Holen I; Croucher PI; Hamdy FC
Prostate; 2004 May; 59(3):304-10. PubMed ID: 15042606
[TBL] [Abstract][Full Text] [Related]
18. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
Taue R; Kanayama H; Kagawa S
Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
[TBL] [Abstract][Full Text] [Related]
19. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
20. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
